RxDoctor Payments Data

Nadine Kassis, MD

Urogynecology and Reconstructive Pelvic Surgery · Toledo, OHNPI 1023276565

Payments from drug & device makers

What this record shows

This record is dominated by education: $12,425 of the $14,825 with a category attached, or 83.8%. Intuitive Surgical accounts for 87.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $10,029 and has fallen 97.8% since, to $219 in 2025.

$14,825in general payments, 2019–2025

Across 95 payments — averaging $156.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Astellas Pharma US Inc$896
  • Abbott$162
  • AbbVie$130
  • Pfizer$114
  • Sumitomo Pharma America, Inc.$105
  • plus $447 from 13 others

What the payments were for

  • Travel & lodging$7565%
  • Food & beverage$1,64511%
  • Education$12,42584%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,825 in reported general payments places this provider in the 80th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

See all urogynecology and reconstructive pelvic surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$123,024
Medicare patients
302
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron252$155,553
GemtesaVibegron40$29,426
Mirabegron ErMirabegron32$18,961
Estradiol125$9,276
Solifenacin Succinate154$7,902
PremarinEstrogens, Conjugated14$6,091
Trimethoprim125$4,797
Oxybutynin Chloride ErOxybutynin Chloride140$4,383
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst130$3,097
Tolterodine Tartrate ErTolterodine Tartrate12$1,674
Cephalexin112$427
Methenamine Hippurate11$404
Clobetasol Propionate14$366
Oxybutynin Chloride21$289
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim66$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$896$155,553252 claims
Sumitomo Pharma America, Inc.Gemtesa$105$29,42640 claims
PfizerPremarin$114$6,09114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

Other urogynecology and reconstructive pelvic surgery in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →